Abstract: Immunoglycoproteins, including antibodies, with improved ADCC and altered glycosylation patterns are provided. Also provided are cell culturing methods and media for producing such immunoglycoproteins, and therapeutic uses of such immunoglycoproteins.

Abstract: The invention relates to a Flexible Intermediate Bulk Container (FIBC) having a body made of flexible woven fabric, and integral handling devices, wherein the fabric is woven from opaque oriented polyethylene terephthalate (PET) strips having a density of from 500 to 1300 kg/m3 and a tensile strength of at least 250 MPa. Advantages of said FIBC include directly printability with the usual type of inks, giving excellent contrast and good adhesion, without pre-treatment like a corona- or flame-treatment. The FIBC based on the PET fabric also shows higher gloss; better UV resistance; better mechanical properties, like high tensile strength and creep resistance; favourable abrasion resistance; and higher temperature resistance than a conventional big bag based on polypropylene strips. The invention further relates to such a FIBC based on stress-whitened PET tapes obtained by a special drawing process.

Abstract: The invention relates to a process for making an opaque and glossy film from a thermoplastic polyester composition, comprising the steps of a) extruding the polyester composition through a slot die, and quenching to form a substantially amorphous film having a crystallinity of at most 5%; b) rapidly heating the amorphous film to a drawing temperature in the range from Tg to (Tg+50)° C. while applying a draw ratio in the range of from ?initiation to ?max. in longitudinal direction, and a drawing rate of at least 1 m/min to form an oriented film showing stress-whitening, wherein ?initiation is the draw ratio at which a transfer from a transparent product to a stress-whitened product occurs and ?max. is the draw ratio at which failure of the stress whitened film occurs; and c) heat-setting the oriented stress-whitened film; the thermoplastic polyester composition substantially consisting of at least one crystallisable polyester derived from at least one aliphatic diol and at least one aromatic dicarboxylic acid.

Abstract: Methods, apparatus, and computer-readable media employing computer-readable components for localization of data included in software programs are described. The computer-readable components comprise data elements defined based on a software data schema; and an owned comment data element comprising information about the localization of the data included in the software programs and an associated owner with permission to create, access, and manipulate the owned comment data element. The owned comment data element is included in other data elements. The owned comment data element may also be included in a list of owned comment elements comprising at least one owned comment data element.

Abstract: A method of removing the imaging drum (2) of a desktop laser printer and the like wherein pressure is applied to either one or both of the stub bearings (5) of the imaging drum mounted in support bearings (7) attached to the body of the printer cartridge to dislodge the stub bearings and thereafter the application of pressure is continued to force the stub bearings out of their support bearings to allow the drum to be released. This avoids the disadvantages of present known methods one of which involves sawing through the imaging drum and then sliding the two cut halves out of their respective bearings in the printer cartridge.

Abstract: A sealing system for a pump having a plunger includes a housing having an internal chamber adapted to receive a portion of the plunger. Primary and secondary seals are located within the internal chamber and adapted to sealingly engage the plunger. The primary seal communicates with the fluid being pumped. A barrier fluid chamber contains a barrier fluid in contact with the primary seal and the secondary seal. A pressure referencing device has an inlet port in communication with the pumped fluid and an outlet port providing fluid at a pressure magnitude equal to a peak pressure of the pumped fluid. A pressurizing device is in communication with the fluid at the peak pressure and the barrier fluid to maintain the barrier fluid pressure at a magnitude greater than the peak pressure of the pumped fluid such that the pumped fluid is restricted from leaking past the primary seal.

Abstract: A sealing system for a pump having a plunger includes a housing having an internal chamber adapted to receive a portion of the plunger. Primary and secondary seals are located within the internal chamber and adapted to sealingly engage the plunger. The primary seal communicates with the fluid being pumped. A barrier fluid chamber contains a barrier fluid in contact with the primary seal and the secondary seal. A pressure referencing device has an inlet port in communication with the pumped fluid and an outlet port providing fluid at a pressure magnitude equal to a peak pressure of the pumped fluid. A pressurizing device is in communication with the fluid at the peak pressure and the barrier fluid to maintain the barrier fluid pressure at a magnitude greater than the peak pressure of the pumped fluid such that the pumped fluid is restricted from leaking past the primary seal.

Abstract: A sealing system for a pump includes a housing having an internal chamber adapted to receive a portion of a plunger. A primary seal is translatable within the chamber in sealing relation with the housing. The primary seal includes first and second elastomeric members adapted to sealingly engage the plunger. The first and second elastomeric members are spaced apart from one another a distance greater than or equal to a maximum stroke of the plunger. A secondary seal is spaced apart from the primary seal and adapted to sealingly engage the plunger. A chamber contains a barrier fluid in contact with the primary seal and the secondary seal. A pressurizing device maintains a pressure of barrier fluid at a magnitude greater than a peak pressure of a fluid pumped by the plunger such that the pumped fluid is restricted from entering the barrier fluid chamber.

Abstract: A sealing system for a pump having a plunger includes a housing having an internal chamber adapted to receive a portion of the plunger. Primary and secondary seals are located within the internal chamber and adapted to sealingly engage the plunger. The primary seal communicates with the fluid being pumped. A barrier fluid chamber contains a barrier fluid in contact with the primary seal and the secondary seal. A pressure referencing device has an inlet port in communication with the pumped fluid and an outlet port providing fluid at a pressure magnitude equal to a peak pressure of the pumped fluid. A pressurizing device is in communication with the fluid at the peak pressure and the barrier fluid to maintain the barrier fluid pressure at a magnitude greater than the peak pressure of the pumped fluid such that the pumped fluid is restricted from leaking past the primary seal.

Abstract: Methods, apparatus, and computer-readable media including computer-readable components for the localization of data included in software programs are described. The computer-readable components comprise data elements defined by a software data schema; a property repository data element for storing a plurality of data properties about the data elements; and an owned comment data element comprising information about the localization of the data included in software programs and an owner with permission to create, access, and manipulate the owned comment data element.

Abstract: The present disclosure provides methods for using CD37-specific binding molecules (such as a CD37-specific SMIP or antibody) in combination with mTOR inhibitors (such as rapamycin and derivatives or analogues thereof) or phosphatidylinositol 3-kinase (PI3K) inhibitors (such as p110?-specific inhibitors or the like), which can be done concurrently or sequentially, to treat or prevent a B-cell related hyperproliferative disease, such as a lymphoma, carcinoma, myeloma, or the like.

Abstract: A communication method, for use with a telecommunications system, enables special communications to be routed to respective devices in a group of the devices by addressing the devices with a respective special identifier. The telecommunications system includes a network core and a plurality of subscriber devices registered with the network core. The core enables communications to be routed to the devices by a respective ID allocated to each device. The method further includes maintaining a store of the special identifier of each device in the group and a corresponding value derived from the ID. The method enables the special identifier of a device in the group to be obtained from the store by providing the store with the corresponding value derived from that device's ID.

Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high express levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.

Abstract: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.

Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.

Abstract: The present application provides novel binding proteins, including human binding proteins that specifically bind to the human ErbB2.

Abstract: The communications system is disclosed that includes a plurality of devices associated in a group. A server (50) administers communications between members of the group. Preferably, member devices of the group are provided with a client application (52) for communicating with the server (50). In the embodiment the client application is installed on a mobile or cellular telecommunications device, such as a GPRS or 3G mobile handset. The client facilitates communications of the user of the handset with the server, and provides an interface between the underlying device functionality (such as a built-in camera, the device's file system etc.) to allow content to be easily accessed and shared amongst members of the group. Communications between the client application and the server may be performed by XML over HTTP using a GPRS or 3G bearer.

Abstract: The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.

Abstract: The invention relates to novel binding domain-immunoglobulin fusion proteins that feature a binding domain for a cognate structure such as an antigen, a counterreceptor or the like, a wild-type IgG1, IGA or IgE hinge-acting region, i.e., IgE CH2, region polypeptide or a mutant IgG1 hinge region polypeptide having either zero, one or two cysteine residues, and immunoglobulin CH2 and CH3 domains, and that are capable of ADCC and/or CDC while occurring predominantly as polypeptides that are compromised in their ability to form disulfide-linked multimers. The fusion proteins can be recombinantly produced at high expression levels. Also provided are related compositions and methods, including cell surface forms of the fusion proteins and immunotherapeutic applications of the fusion proteins and of polynucleotides encoding such fusion proteins.

Abstract: Multivalent binding peptides, including bi-specific binding peptides, having immunoglobulin effector function are provided, along with encoding nucleic acids, vectors and host cells as well as methods for making such peptides and methods for using such peptides to treat or prevent a variety of diseases, disorders or conditions, as well as to ameliorate at least one symptom associated with such a disease, disorder or condition.